Cancer vaccine market to hit $7B by 2015

Spurred by the recent approval of Dendreon's prostate cancer vaccine Provenge, a new report predicts that the cancer vaccine market will swell to a $7 billion industry by 2015. There are six types of vaccines in development, according to the report: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. Release